Retatrutide, a novel dual-acting glucose-regulated incretin analog, represents a significant progression in peptide therapeutics for the management of type 2 diabetic conditions and, increasingly, excess adiposity. Unlike many existing therapeutic interventions, retatrutide merges the actions of a GLP-1 receptor activator and a GIP receptor activat